Lotus Pharmaceutical - Public Comps and Valuation Multiples

Lotus Pharmaceutical Overview

About Lotus Pharmaceutical

Lotus Pharmaceutical Co Ltd is engaged in the healthcare sector. The only reportable segment of the company is the Pharmaceuticals business segment, which engages mainly in the research and development, manufacturing and sales of pharmaceutical products. It has a geographic presence in the United States, Malta, Taiwan, and Others.

Founded

1966

HQ

Employees

750

Website

lotuspharm.com

Sectors

Biopharmaceuticals
Drug Development & Therapeutics
BioTech

Financials

LTM Revenue $620M

LTM EBITDA $253M

EV

$3.0B

Valuation Multiples

Multiples.vc

Valuation Multiples for 15K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Browse Valuation Multiples

Lotus Pharmaceutical Financials

As of December 2025, Lotus Pharmaceutical reported last 12-month revenue of $620M and EBITDA of $253M.

In the same period, Lotus Pharmaceutical generated $373M in LTM gross profit and $157M in net income.

See Lotus Pharmaceutical valuation multiples based on analyst estimates

Lotus Pharmaceutical P&L

In the most recent fiscal year, Lotus Pharmaceutical reported revenue of $590M and EBITDA of $261M.

Lotus Pharmaceutical expects next 12-month revenue of XXX and NTM EBITDA of XXX

See Lotus Pharmaceutical valuation multiples based on analyst estimates

	LTM	NTM	Last FY	FY 2026	FY 2027	FY 2028
Revenue	$620M	XXX	$590M	XXX	XXX	XXX
Gross Profit	$373M	XXX	$347M	XXX	XXX	XXX
Gross Margin	60%	XXX	59%	XXX	XXX	XXX
EBITDA	$253M	XXX	$261M	XXX	XXX	XXX
EBITDA Margin	41%	XXX	44%	XXX	XXX	XXX
EBIT	$199M	XXX	$191M	XXX	XXX	XXX
EBIT Margin	32%	XXX	32%	XXX	XXX	XXX
Net Profit	$157M	XXX	$161M	XXX	XXX	XXX
Net Margin	25%	XXX	27%	XXX	XXX	XXX
Net Debt	XXX	XXX	$234M	XXX	XXX	XXX

Financial data powered by Morningstar, Inc.

.seo-only-financials-wrapper { position: static; left: auto; width: auto; height: auto; overflow: visible; }

Financial performance metrics for Lotus Pharmaceutical including revenue, profitability, and margin analysis across different time periods. The company reported last twelve months revenue of $620M. EBITDA for the last twelve months was $253M. In the most recent fiscal year, Lotus Pharmaceutical achieved $590M in revenue and $261M in EBITDA.
Financial Metric	Last Twelve Months (LTM)	Next Twelve Months (NTM)	Most Recent Fiscal Year	Current Fiscal Year (2026)	Next Fiscal Year (2027)	Two Years Forward (2028)
Total Revenue	$620M	Analyst estimates available to subscribers	$590M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Gross Profit	$373M	Analyst estimates available to subscribers	$347M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Gross Profit Margin	60.2% gross margin	Analyst estimates available to subscribers	58.8% gross profit margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBITDA (Earnings Before Interest, Taxes, Depreciation, Amortization)	$253M	Analyst estimates available to subscribers	$261M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBITDA Margin	40.7% EBITDA margin	Analyst estimates available to subscribers	44.2% EBITDA margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBIT (Earnings Before Interest and Taxes)	$199M	Analyst estimates available to subscribers	$191M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBIT Margin	32.0% EBIT margin	Analyst estimates available to subscribers	32.4% EBIT margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Income (Net Profit)	$157M	Analyst estimates available to subscribers	$161M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Profit Margin	25.3% net profit margin	Analyst estimates available to subscribers	27.3% net profit margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Debt Position	Detailed debt information available to subscribers	Detailed debt information available to subscribers	$234M	Detailed debt information available to subscribers	Detailed debt information available to subscribers	Detailed debt information available to subscribers

Financial Performance Summary for Lotus Pharmaceutical

This financial data table provides comprehensive performance metrics for Lotus Pharmaceutical, a company based in Taiwan. The metrics include revenue, profitability measures, and operational efficiency indicators across multiple time periods.

Recent Performance Highlights

Lotus Pharmaceutical generated $620M in revenue over the last twelve months.
The company achieved $253M in EBITDA over the last twelve months.
Gross profit for the last twelve months was $373M.
Net income over the last twelve months reached $157M.

Fiscal Year Performance

In the most recent fiscal year, Lotus Pharmaceutical reported $590M in total revenue.
Fiscal year EBITDA was $261M.
The company maintained a gross profit margin of 58.8% in the most recent fiscal year.
EBITDA margin for the fiscal year was 44.2%.
Net profit margin reached 27.3% in the most recent fiscal year.

This financial data is sourced from Morningstar, Inc. and represents the most recent available information for Lotus Pharmaceutical. Forward-looking estimates and detailed financial projections are available through our premium subscription service.

Lotus Pharmaceutical Stock Performance

Lotus Pharmaceutical has current market cap of TWD 88.7B (or $2.8B), and EV of TWD 95.4B (or $3.0B).

Market Cap Evolution

Lotus Pharmaceutical Stock Data

As of January 16, 2026, Lotus Pharmaceutical's stock price is TWD 338 (or $11).

See Lotus Pharmaceutical trading valuation data

EV	Market Cap	Price 1D	Price 1M	Price 3M	Price 12M	EPS
$3.0B	$2.8B	XXX	XXX	XXX	XXX	$0.59

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Start Free Trial

Lotus Pharmaceutical Valuation Multiples

Lotus Pharmaceutical's trades at 4.9x EV/Revenue multiple, and 12.0x EV/EBITDA.

See valuation multiples for Lotus Pharmaceutical and 15K+ public comps

Lotus Pharmaceutical Financial Valuation Multiples

As of January 16, 2026, Lotus Pharmaceutical has market cap of $2.8B and EV of $3.0B.

Equity research analysts estimate Lotus Pharmaceutical's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

Lotus Pharmaceutical has a P/E ratio of 17.9x.

	LTM	NTM	Last FY	FY 2026	FY 2027	FY 2028
Market cap (current)	$2.8B	XXX	$2.8B	XXX	XXX	XXX
EV (current)	$3.0B	XXX	$3.0B	XXX	XXX	XXX
EV/Revenue	4.9x	XXX	4.9x	XXX	XXX	XXX
EV/EBITDA	12.0x	XXX	12.0x	XXX	XXX	XXX
EV/EBIT	15.3x	XXX	15.3x	XXX	XXX	XXX
EV/Gross Profit	8.1x	XXX	n/a	XXX	XXX	XXX
P/E	17.9x	XXX	17.9x	XXX	XXX	XXX
EV/FCF	17.6x	XXX	17.6x	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Lotus Pharmaceutical Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Start Free Trial

Lotus Pharmaceutical Margins & Growth Rates

Lotus Pharmaceutical's last 12 month revenue growth is 75%

Lotus Pharmaceutical's revenue per employee in the last FY averaged $0.8M, while opex per employee averaged $0.2M for the same period.

Lotus Pharmaceutical's rule of 40 is 116% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Lotus Pharmaceutical's rule of X is 229% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

See operational valuation multiples for Lotus Pharmaceutical and other 15K+ public comps

Lotus Pharmaceutical Operational Valuation Multiples

	LTM	NTM	Last FY	FY 2026	FY 2027	FY 2028
Revenue Growth	75%	XXX	40%	XXX	XXX	XXX
EBITDA Margin	41%	XXX	41%	XXX	XXX	XXX
EBITDA Growth	51%	XXX	8%	XXX	XXX	XXX
Rule of 40	116%	XXX	116%	XXX	XXX	XXX
Bessemer Rule of X	XXX	XXX	229%	XXX	XXX	XXX
Revenue per Employee	XXX	XXX	$0.8M	XXX	XXX	XXX
Opex per Employee	XXX	XXX	$0.2M	XXX	XXX	XXX
S&M Expenses to Revenue	XXX	XXX	14%	XXX	XXX	XXX
G&A Expenses to Revenue	XXX	XXX	n/a	XXX	XXX	XXX
R&D Expenses to Revenue	XXX	XXX	4%	XXX	XXX	XXX
Opex to Revenue	XXX	XXX	26%	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics

Pharma Analytics

Private Equity

ERP Software

Developer Tools

Consumer SaaS

Streaming Platforms

Explore Valuation Multiples by Industry

Start Free Trial